Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981635 | 0.79 | PLA2G1B (0.41) | PLA2G1BPLA2G2A | |
| SCHEMBL16209737 | 0.79 | PLA2G1B (0.41) | PLA2G1BPLA2G2A | |
| SCHEMBL14992952 | 0.79 | PLA2G1B (0.41) | PLA2G1BPLA2G2A | |
| SCHEMBL3697268 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL28894485 | 0.74 | PLA2G1B (0.41) | PLA2G1BPLA2G2ATSHRNPY1RNPY2R | |
| SCHEMBL8780307 | 0.74 | TSHR (0.33) | PLA2G1BPLA2G2ATSHRNPY1RNPY2R | |
| SCHEMBL3104259 | 0.74 | MAPT (0.34) | PLA2G1BPLA2G2ATSHRNPY1RNPY2R | |
| SCHEMBL5886313 | 0.74 | — | — | |
| SCHEMBL5886507 | 0.74 | — | — | |
| SCHEMBL18158073 | 0.73 | PLA2G1B (0.38) | PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | PLA2G1B 4806/4885PLA2G2A 4662/4885TSHR 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.